Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011777 · ClinicalTrials.gov registry record · Phase 1
Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01011777: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT01011777 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011777, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The aim of this study is to study safety, tolerability and efficacy of muscle derived cell (MDC) therapy in children with bladder exstrophy epispadias induced urinary incontinence.
Interventions
- DRUG MDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011777
The ClinicalTrials.gov registry entry for NCT01011777 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDC is the first listed.
NCT01011777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011777 about?
NCT01011777 is a clinical study titled "Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence". The aim of this study is to study safety, tolerability and efficacy of muscle derived cell (MDC) therapy in children with bladder exstrophy epispadias induced urinary incontinence.
What is the current status of trial NCT01011777?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-02-01. Estimated completion is 2020-01-23.
What interventions are being tested in trial NCT01011777?
The interventions under investigation include: MDC (DRUG).
Who is sponsoring clinical trial NCT01011777?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.